Penumbra Inc.
Penumbra Appoints New Auditor and Dismisses Previous Auditor
Summary
Penumbra, Inc. announced on March 17, 2024, that it has appointed PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024, and dismissed Deloitte & Touche LLP. The dismissal of Deloitte did not involve any disagreements or reportable events. Deloitte's reports on the consolidated financial statements for fiscal years 2023 and 2022 did not contain any adverse opinions or disclaimers. The decision to appoint PwC was made with the approval of the Audit Committee and is subject to PwC's completion of its standard client acceptance procedures.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement